This move is archived. Current quotes and coverage live on the stock page.
Get BLCO alerts:
Bausch + Lomb Corp's stock increased by 3.06% in the last trading session, reflecting positive investor sentiment.
In the latest trading session, Bausch + Lomb Corp (BLCO.TO) closed at CA$21.24, showing a significant uptick. This rise follows strategic developments that have boosted investor confidence in the company’s future prospects.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.87B
52W high
$25.70
52W low
$19.36
1W change
+5.17%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 1.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.07
+1.0% Upside
Current Price
C$24.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.8%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$29.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$26.35 | C$24.45 – C$28.41 |
| 60 trading days | C$27.97 | C$25.15 – C$31.10 |
| 90 trading days | C$29.68 | C$26.07 – C$33.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of Bausch + Lomb's recent strategic financing involvement with Emmecell, which may enhance its position in the ophthalmic treatment market.
Bausch + Lomb Corp Stock Climbs 3.06%
The stock's rise to CA$21.24 reflects growing optimism among investors, driven by strategic partnerships and advancements in technology.
Bull case
The successful closing of a strategic financing round involving Bausch + Lomb and Emmecell shows the company's commitment to innovation in ophthalmic therapies. This could lead to increased market share and revenue growth.
Bear case
Despite the positive movement, Bausch + Lomb faces ongoing challenges with profitability and a negative profit margin, which may raise concerns about its long-term financial health.
Advertisement
Strategic Financing with Emmecell
Bausch + Lomb's participation in Emmecell's recent financing round highlights its dedication to advancing innovative treatments for corneal diseases. This partnership may pave the way for new therapies that address significant unmet needs in ophthalmology.
Market Response and Future Outlook
The market's positive response to Bausch + Lomb's stock reflects investor confidence in its growth trajectory. As the company continues to invest in cutting-edge technologies, it could enhance its competitive edge in the healthcare sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
